权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Antidepressants and Intracellular Signaling Linked to BDNF

抗抑郁药和与 BDNF 相关的细胞内信号传导

基本信息

批准号：
10363271
负责人：
LISA M MONTEGGIA
金额：
$ 53.21万
依托单位：
VANDERBILT UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2005
资助国家：
美国
起止时间：
2005-07-01 至 2027-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10363271
关键词：
AMPA Receptors Acids Acute Affect Affinity Animals Antidepressive Agents Attenuated Behavior Behavioral Brain Brain-Derived Neurotrophic Factor C57BL/6 Mouse Chemosensitization Chronic Clinical Data Depressed mood Development Electrophysiology (science)Excitatory Postsynaptic Potentials Funding Genetic Polymorphism Glutamates Grant Hippocampus (Brain)In Vitro Infusion procedures Instruction Ketamine Knockout Mice Link Mediating Mediator of activation protein Mental Depression Molecular Mus N-Methyl-D-Aspartate Receptors N-Methylaspartate Neuronal Plasticity Neurons Neurotrophic Tyrosine Kinase Receptor Type 2 Patients Peptide Elongation Factor 2 Phosphorylation Phosphotransferases Postsynaptic Membrane Pre-Clinical Model Property Prosencephalon Protein Dephosphorylation Proteins Receptor Activation Regulation Repression Research Rest Role Signal Transduction Synapses Synaptic Transmission Synaptic plasticity Testing Transcript Translations Wild Type Mouse Work antagonist antidepressant effect base calmodulin-dependent protein kinase III channel blockers clinical efficacy in vivo insight kinase inhibitor neurotransmission neurotrophic factor novel receptor response sensor synaptic function treatment-resistant depression

项目摘要

Project Summary In the previous funding period we investigated the mechanism of rapid antidepressant activity of ketamine, an ionotropic glutamatergic n-methyl-d-aspartate (NMDA) receptor antagonist. We demonstrated that Brain- derived neurotrophic factor (BDNF), and its high affinity receptor TrkB, are required for the rapid antidepressant effects of ketamine as these effects are lost in forebrain specific BDNF knockout mice and conditional forebrain specific TrkB knockout mice. We found the antidepressant effects of ketamine require protein translation, but not transcription, resulting in increases in BDNF protein levels in the hippocampus that are critical for the behavioral effect. Ketamine's blockade of spontaneous NMDA receptor mediated neurotransmission inactivates eukaryotic elongation factor 2 kinase (eEF2K) resulting in dephosphorylation of its only known substrate, eukaryotic elongation factor 2, thereby increasing protein translation of target transcripts, including BDNF. In turn, BDNF is postulated to act via eliciting insertion of 3-hydroxy-5-methyl-4- isoxazolepropionic acid (AMPA) receptors at the postsynaptic membrane, which results in potentiation of AMPA receptor-mediated CA3-CA1 field excitatory postsynaptic potentials (fEPSPs) by ketamine. While this potentiation is suggested to be a cellular correlate of rapid antidepressant effects, its properties deviate from classical Hebbian forms of plasticity and rather coincide with homeostatic synaptic scaling seen after activity suppression. These data provide the basis for the novel hypothesis that BDNF-TrkB signaling regulates synaptic scaling in vivo that is critical for the rapid antidepressant effects of ketamine. The objective of this renewal is to specifically test the causal and instructive role of BDNF-TrkB signaling in the hippocampus in ketamine-mediated synaptic scaling and rapid antidepressant effects. Collectively, this information will provide novel information on the synaptic locus, as well as key molecules, necessary for ketamine's rapid antidepressant effects.

项目总结